Drug Development Updates

Stay informed with timely notifications on clinical trials and research advancements.

Doravirine lamivudine、tenofovir disoproxil fumarate

Generic Name: Doravirine lamivudine、tenofovir disoproxil fumarate

Overview

No overview information available.

Background

No background information available.

Indication

用于治疗18岁以上人群HIV（人类免疫缺陷病毒）感染。

Associated Conditions

No associated conditions information available.

Clinical Trials

A Randomised, Phase 3 Non-inferiority Study of DOR/3TC/TDF Compared to DTG/TAF/FTC in Participants Infected With HIV-1 Starting First-line Antiretroviral Therapy

Phase 3

Active, not recruiting

Posted: 2023/06/29

Sponsor:

Professor Francois V...

ID:NCT05924438

The Effect on Lipid Profile of Switching to Delstrigo in HIV Positive Patients

Phase 4

Terminated

Posted: 2022/03/22

Sponsor:

Chelsea and Westmins...

ID:NCT05289986

DORA: A Doravirine-based First-line Antiretroviral Therapy for Women of Reproductive Potential Living With HIV

Phase 3

Completed

Posted: 2020/06/16

Sponsor:

Professor Francois V...

ID:NCT04433780

Evaluation of (Doravirine / Lamivudine / Tenofovir Disoproxil Fumarate) (Delstrigo®) as a New Strategy for Non-occupational Post Exposure Prophylaxis, a Prospective Open Label Study

Phase 4

Posted: 2020/01/18

Sponsor:

David Garcia Cinca

ID:NCT04233372

Islatravir (MK-8591) With Doravirine and Lamivudine in Participants Infected With Human Immunodeficiency Virus Type 1 (MK-8591-011)

Phase 2

Completed

Posted: 2017/09/05

Sponsor:Merck Sharp & Dohme ...

ID:NCT03272347

FDA Approved Products

No FDA products found for this drug

Singapore Approved Products

No Singapore products found for this drug

Related News

No news found

Drug Development Updates

Stay informed with timely notifications on clinical trials and research advancements.

Home Terms & Conditions Privacy Policy